Overview

Update
IPO / Stock
Went Public on May 27, 2004 / NASDAQ:ACAD
Total Equity Funding
$25M in 1 Round from 6 Investors
Headquarters:
San Diego, CA
Description:
ACADIA Pharmaceuticals develops and commercializes small molecule drugs for the treatment of central nervous system disorders.
Categories:
Pharmaceutical, Health Care, Biotechnology
Website:
http://www.acadia-pharm.com
Social:

Company Details

Update

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

Funding Rounds (3) - $126.39M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jan, 2013$86.39M / Post Ipo Equity0
Jan, 2011$15M / Post Ipo Equity2
Mar, 2003$25M / Series F6

Current Team (5)

Update

Offices/Locations (1)

Update
  • Headquarters

    3911 Sorrento Valley Blvd

    San Diego, CA 92121

    USA

Past Team (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos